$38.120
+0.061 (+0.16%)At close
NVO News
NVO Events
Evotec Appoints Joanna Holbrook as Chief Scientific Officer
Evotec (EVO) announced the appointment of Joanna Holbrook as chief scientific officer and member of the management board, effective November 1. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk (NVO).
Novo Nordisk Shares Up 0.39% to $37.55
Moderately bullish activity in Novo Nordisk (NVO), with shares up 14c, or 0.39%, near $37.55. Options volume relatively light with 6894 contracts traded and calls leading puts for a put/call ratio of 0.41, compared to a typical level near 0.79. Implied volatility (IV30) is higher by 0.9 points near 33.33,in the lowest 10% of observations over the past year, suggesting an expected daily move of $0.79. Put-call skew steepened, indicating increased demand for downside protection.
Novo Nordisk Shares Slightly Down, Options Activity Moderate
Moderately bullish activity in Novo Nordisk (NVO), with shares down 34c near $37.56. Options volume relatively light with 29k contracts traded and calls leading puts for a put/call ratio of 0.54, compared to a typical level near 0.75. Implied volatility (IV30) is higher by 1.7 points near 32.44,in the lowest 10% of observations over the past year, suggesting an expected daily move of $0.77. Put-call skew flattened, suggesting a modestly bullish tone.
Novo Nordisk Shares Slightly Down, Options Activity Moderate
Moderately bullish activity in Novo Nordisk (NVO), with shares down 40c near $37.91. Options volume roughly in line with average with 54k contracts traded and calls leading puts for a put/call ratio of 0.7, compared to a typical level near 0.75. Implied volatility (IV30) is higher by 0.4 points near 30.72,in the lowest 10% of observations over the past year, suggesting an expected daily move of $0.73. Put-call skew flattened, suggesting a modestly bullish tone.
Novo Nordisk Announces CagriSema Study Data, 22.4% Weight Reduction at 52 Weeks
The company states: "Novo Nordisk announced new data on how CagriSema works inside both the brain and body, presented at the European Association for the Study of Diabetes Annual Meeting 2026. In a 52-week functional magnetic resonance imaging (fMRI) study, a brain scan technique that shows how the brain responds to cues, in adults with overweight or obesity, CagriSema modified brain responses to high-calorie food cues in regions linked to cravings, reward, sensory processing and behavioural control. Additionally, CagriSema substantially improved eating behaviour, reduced 'food noise', cravings, hunger, appetite, and food-related thoughts and improved craving control after both 22 and 52 weeks of treatment. In the study, also awarded a Best Abstract Award at EASD 2026, the improvements were also associated with a 22.4% reduction in body weight versus placebo at 52 weeks (estimated treatment difference at 52 weeks, pless than0.0001). Overall, the results suggest CagriSema may help address biological drivers that make sustained weight management difficult, including hunger, cravings and food preoccupation, not just calorie intake. Separately, in a diabetes MRI sub-study, which evaluated whole body metabolic effects in the phase 3a REIMAGINE 1 trial in adults with early type 2 diabetes, CagriSema 2.4 mg/2.4 mg produced significant reductions in fat in the abdomen and around the liver and pancreas fat versus placebo, alongside a 14.3% body-weight reduction at week 40. In addition, a post hoc analysis of bone markers of the phase 3 REIMAGINE 2 trial in adults with inadequately controlled type 2 diabetes showed signs of healthy balance in bone maintenance alongside a 14.2% body-weight reduction with CagriSema 2.4 mg/2.4 mg at week 68, providing what the study authors describe as "preliminary reassurance regarding bone changes with CagriSema in type 2 diabetes"."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.